Abstract
AIMS: Many sarcoidosis patients experience a reduction in health-related quality of life (HRQoL) and a majority of patients report fatigue. Historically, drug trials in sarcoidosis have focused on changes in chest radiographs, lung function parameters and biomarkers, while HRQoL and fatigue have not been the main outcomes examined. We performed a systematic review of the literature to evaluate the existing evidence on the effects of pharmacological interventions on HRQoL and fatigue outcomes.
METHODS: The systematic search was performed in Medline and Embase and yielded 15 records covering seven randomised controlled trials and seven single-arm open label studies, which were included in a qualitative synthesis (the results of one study were included in two publications). 12 studies evaluated immunosuppressive and/or immunomodulatory therapies and two studies evaluated stimulants.
RESULTS: Nine out of the 14 studies observed positive treatment effects from the interventions on HRQoL and/or fatigue, exceeding the minimal important difference. The risk of bias was generally high with only three studies rated as having a low risk of bias. The results suggest a potential for improvement in HRQoL and/or fatigue in patients with active disease who are either untreated or treated but not yet fully stabilised or therapy refractory.
CONCLUSION: More randomised, double-blind and placebo-controlled trials are needed to expand the evidence base on these important outcome parameters.
| Original language | English |
|---|---|
| Article number | 190057 |
| Number of pages | 14 |
| Journal | European Respiratory Review |
| Volume | 29 |
| Issue number | 155 |
| DOIs | |
| Publication status | Published - 29 Jan 2020 |
Fingerprint
Dive into the research topics of 'The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review'. Together they form a unique fingerprint.
View full fingerprint
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
Vis, R., van de Garde, E. M. W., Grutters, J. C., & Korenromp, I. H. E. (2020). The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review. European Respiratory Review, 29(155), Article 190057. https://doi.org/10.1183/16000617.0057-2019
Vis, Roeland ; van de Garde, Ewoudt M W ; Grutters, Jan C et al. / The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis : a systematic review. In: European Respiratory Review. 2020 ; Vol. 29, No. 155.
@article{596fe5335597439c8b0679e733e45062,
title = "The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review",
abstract = "AIMS: Many sarcoidosis patients experience a reduction in health-related quality of life (HRQoL) and a majority of patients report fatigue. Historically, drug trials in sarcoidosis have focused on changes in chest radiographs, lung function parameters and biomarkers, while HRQoL and fatigue have not been the main outcomes examined. We performed a systematic review of the literature to evaluate the existing evidence on the effects of pharmacological interventions on HRQoL and fatigue outcomes.METHODS: The systematic search was performed in Medline and Embase and yielded 15 records covering seven randomised controlled trials and seven single-arm open label studies, which were included in a qualitative synthesis (the results of one study were included in two publications). 12 studies evaluated immunosuppressive and/or immunomodulatory therapies and two studies evaluated stimulants.RESULTS: Nine out of the 14 studies observed positive treatment effects from the interventions on HRQoL and/or fatigue, exceeding the minimal important difference. The risk of bias was generally high with only three studies rated as having a low risk of bias. The results suggest a potential for improvement in HRQoL and/or fatigue in patients with active disease who are either untreated or treated but not yet fully stabilised or therapy refractory.CONCLUSION: More randomised, double-blind and placebo-controlled trials are needed to expand the evidence base on these important outcome parameters.",
author = "Roeland Vis and {van de Garde}, {Ewoudt M W} and Grutters, {Jan C} and Korenromp, {Ingrid H E}",
note = "Copyright {\textcopyright}ERS 2020.",
year = "2020",
month = jan,
day = "29",
doi = "10.1183/16000617.0057-2019",
language = "English",
volume = "29",
journal = "European Respiratory Review",
issn = "0905-9180",
publisher = "European Respiratory Society",
number = "155",
}
Vis, R, van de Garde, EMW, Grutters, JC & Korenromp, IHE 2020, 'The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review', European Respiratory Review, vol. 29, no. 155, 190057. https://doi.org/10.1183/16000617.0057-2019
The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review. / Vis, Roeland; van de Garde, Ewoudt M W; Grutters, Jan C et al.
In: European Respiratory Review, Vol. 29, No. 155, 190057, 29.01.2020.
Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis
T2 - a systematic review
AU - Vis, Roeland
AU - van de Garde, Ewoudt M W
AU - Grutters, Jan C
AU - Korenromp, Ingrid H E
N1 - Copyright ©ERS 2020.
PY - 2020/1/29
Y1 - 2020/1/29
N2 - AIMS: Many sarcoidosis patients experience a reduction in health-related quality of life (HRQoL) and a majority of patients report fatigue. Historically, drug trials in sarcoidosis have focused on changes in chest radiographs, lung function parameters and biomarkers, while HRQoL and fatigue have not been the main outcomes examined. We performed a systematic review of the literature to evaluate the existing evidence on the effects of pharmacological interventions on HRQoL and fatigue outcomes.METHODS: The systematic search was performed in Medline and Embase and yielded 15 records covering seven randomised controlled trials and seven single-arm open label studies, which were included in a qualitative synthesis (the results of one study were included in two publications). 12 studies evaluated immunosuppressive and/or immunomodulatory therapies and two studies evaluated stimulants.RESULTS: Nine out of the 14 studies observed positive treatment effects from the interventions on HRQoL and/or fatigue, exceeding the minimal important difference. The risk of bias was generally high with only three studies rated as having a low risk of bias. The results suggest a potential for improvement in HRQoL and/or fatigue in patients with active disease who are either untreated or treated but not yet fully stabilised or therapy refractory.CONCLUSION: More randomised, double-blind and placebo-controlled trials are needed to expand the evidence base on these important outcome parameters.
AB - AIMS: Many sarcoidosis patients experience a reduction in health-related quality of life (HRQoL) and a majority of patients report fatigue. Historically, drug trials in sarcoidosis have focused on changes in chest radiographs, lung function parameters and biomarkers, while HRQoL and fatigue have not been the main outcomes examined. We performed a systematic review of the literature to evaluate the existing evidence on the effects of pharmacological interventions on HRQoL and fatigue outcomes.METHODS: The systematic search was performed in Medline and Embase and yielded 15 records covering seven randomised controlled trials and seven single-arm open label studies, which were included in a qualitative synthesis (the results of one study were included in two publications). 12 studies evaluated immunosuppressive and/or immunomodulatory therapies and two studies evaluated stimulants.RESULTS: Nine out of the 14 studies observed positive treatment effects from the interventions on HRQoL and/or fatigue, exceeding the minimal important difference. The risk of bias was generally high with only three studies rated as having a low risk of bias. The results suggest a potential for improvement in HRQoL and/or fatigue in patients with active disease who are either untreated or treated but not yet fully stabilised or therapy refractory.CONCLUSION: More randomised, double-blind and placebo-controlled trials are needed to expand the evidence base on these important outcome parameters.
U2 - 10.1183/16000617.0057-2019
DO - 10.1183/16000617.0057-2019
M3 - Review article
C2 - 31996355
SN - 0905-9180
VL - 29
JO - European Respiratory Review
JF - European Respiratory Review
IS - 155
M1 - 190057
ER -
Vis R, van de Garde EMW, Grutters JC, Korenromp IHE. The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review. European Respiratory Review. 2020 Jan 29;29(155):190057. doi: 10.1183/16000617.0057-2019
